- Home
- IKT vs BGX Comparison
IKT vs BGX Comparison
Compare IKT & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- BGX
- Stock Information
- Founded
- IKT 2008
- BGX 2010
- Country
- IKT United States
- BGX United States
- Employees
- IKT N/A
- BGX N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- BGX Trusts Except Educational Religious and Charitable
- Sector
- IKT Health Care
- BGX Finance
- Exchange
- IKT Nasdaq
- BGX Nasdaq
- Market Cap
- IKT 159.2M
- BGX 162.7M
- IPO Year
- IKT 2020
- BGX N/A
- Fundamental
- Price
- IKT $2.31
- BGX $12.77
- Analyst Decision
- IKT Strong Buy
- BGX
- Analyst Count
- IKT 2
- BGX 0
- Target Price
- IKT $6.50
- BGX N/A
- AVG Volume (30 Days)
- IKT 310.9K
- BGX 67.9K
- Earning Date
- IKT 11-14-2024
- BGX 01-01-0001
- Dividend Yield
- IKT N/A
- BGX 10.34%
- EPS Growth
- IKT N/A
- BGX N/A
- EPS
- IKT N/A
- BGX N/A
- Revenue
- IKT $1.00
- BGX N/A
- Revenue This Year
- IKT N/A
- BGX N/A
- Revenue Next Year
- IKT N/A
- BGX N/A
- P/E Ratio
- IKT N/A
- BGX N/A
- Revenue Growth
- IKT N/A
- BGX N/A
- 52 Week Low
- IKT $0.85
- BGX $10.69
- 52 Week High
- IKT $3.82
- BGX $12.44
- Technical
- Relative Strength Index (RSI)
- IKT 52.09
- BGX 50.97
- Support Level
- IKT $1.75
- BGX $12.62
- Resistance Level
- IKT $2.10
- BGX $12.99
- Average True Range (ATR)
- IKT 0.33
- BGX 0.12
- MACD
- IKT -0.10
- BGX 0.01
- Stochastic Oscillator
- IKT 28.87
- BGX 45.00
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About BGX Blackstone Long Short Credit Income Fund
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategy in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first- and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.